Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Making straight the furrow; Pharmaceuticals.(A new boss at troubled Schering-Plough)(Fred Hassan)
- Hassan, the new ploughman Hassan, the new ploughman
- Research articles 2003-04-26
- SCHERING-PLOUGH CORPORATION - Schering-Plough Launches Productivity Transformation Prg.
- Schering-Plough Launches Productivity Transformation Program To Confront New Challenges ...
- Research articles 2008-04-03
- Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs Grew
- About 1,000 sales reps are being let go from Schering-Plough this week. That's on top of 60 animal health reps also being fired. Roughly 5,500 employees in general are being axed in Schering-Plough's cost-cutting drive. If you're one of those people, comfort yourself with the fact that...
- Blog posts 2008-09-19
Additional Resources
- Fred Hassan, Schering's $30 Million Man
- Schering-Plough has had a fairly miserable year so far, thanks to its apparent efforts to keep bad scientific news about the cholesterol pill Vytorin out of the public eye. CEO Fred Hassan, however, is still living off last year's glory -- even if it might well have been far less...
- Blog posts 2008-04-24
- Schering-Plough's Fred Hassan Finally Loses Money on SGP Stock
- It took him five years, but Schering-Plough CEO Fred Hassan has finally lost money on his company's stock. Between 2003 and this year, Hassan bought $6.68 million of SGP common stock and made this vow: This investment in Schering-Plough reflects my long-term confidence in the company, its products --...
- Blog posts 2008-10-09
- MONSANTO COMPANY.(appointed Gary L. Crittenden, Fred Hassan to additional posts)(Brief Article)
- MONSANTO COMPANY and Pharmacia & Upjohn (P&U) have appointed Gary L. Crittenden, Monsanto's senior vice-president and chief financial officer, to the additional ... MONSANTO COMPANY and Pharmacia & Upjohn (P&U) have appointed Gary L. Crittenden, Monsanto's senior vice-president and chief financial officer, to...
- Research articles 2000-01-24
- Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger
- Schering-Plough CEO Fred Hassan stands to receive a potential $59 million payout in his company's merger with Merck, according to a filing with the SEC. The golden parachute comes as the new Merck-Schering entity prepares for $3.5 billion in job cuts and other efficiencies. In Schering's 2008...
- Blog posts 2009-03-09
- Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs Grew
- Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs GrewRE: Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs GrewThis is to correct certain misstatements in your 9/19/08 article in "BNET Industries" involving Schering-Plough CEO Fred Hassan. • Contrary to statements such as “Hassan has still managed to...
- Discussion threads 2008-09-22
- Schering CEO Hassan's Merck Payout Is Millions Greater Than WSJ Thinks It Is
- The Wall Street Journal notes today that in the merger of Merck and Schering-Plough, CEO Fred Hassan "would receive an exit payout of $17.7 million, pension benefits of $13.2 million and medical benefits valued at $130,750." That's a total of about $31 million. But a closer look at the SEC...
- Blog posts 2009-05-22
- Hassan: Congress' duty to fund FDA
- SCHERING-PLOUGH chairman and CEO Fred Hassan has set out an agenda for the newly elected US Congress when it convenes in January.
- Research articles 2007-01-01
- Does J&J's Move on Remicade Pact Threaten Schering CEO Hassan's $51 Mil. Merger Payout?
- Johnson & Johnson filed with an arbitrator to unravel its Remicade distribution agreement with Schering-Plough, in light of the latter's merger with Merck. Schering argues there is no change of control in the agreement, a move which may threaten Schering CEO Fred Hassan's $51 million merger payout. by Jim Edwards
- Blog posts 2009-05-21
- Schering's CEO, a Failed Trial and $16 Million
- Forbes' Matthew Herper and Michael Maiello have just jumped on a subject we alluded to -- perhaps too obliquely -- a few weeks back in discussing the eye-popping $30 million Schering-Plough CEO Fred Hassan pulled down in 2007. Not only did Schering post a $1.5 billion loss that year, it...
- Blog posts 2008-05-20
- Schering-Plough Corp. Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from Chris Schott - Banc of America. Chris Schott - Banc of America First as we look out to 2008 and Medicare part D, can you talk about the initial discussions you're having with payers? First,...
- Earnings calls 2007-07-23
- Schering-Plough Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Tim Anderson. Tim Anderson - Sanford Bernstein Thank you. Couple of questions. On golimunab, if I look at average European approval timelines it suggests you would get a decision in the first half of '09. Is that...
- Earnings calls 2009-02-03
- Schering-Plough Corporation Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Your first question comes from Tim Anderson - Sanford Bernstein. Tim Anderson - Sanford Bernstein Most companies now are reporting their emerging market sales. Can we get the same from Schering? The second question just relates to your comment on boceprevir being best...
- Earnings calls 2009-07-21
- Schering-Plough's Productivity (Layoffs) Program Has Murky Results
- When Schering-Plough declared its Q4 2008 earnings a few days ago, the management team there got about half-a-dozen questions about the company's sales and marketing expenses -- more than the usual number. Schering has played up its Productivity Transformation Program to Wall Street, which is essentially a...
- Blog posts 2009-02-12
- Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?
- Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering’s shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA. In a statement, Schering VP Thomas Koestler said he was “surprised...
- Blog posts 2008-08-01
- Schering-Plough Corporation Q3 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from Tim Anderson - Sanford Bernstein Tim Anderson - Sanford Bernstein I wanted to wish you, Fred, and the others well in your next endeavor whatever that’s going to be. The first question is whether you can give us an inkling...
- Earnings calls 2009-10-22
- Schering Plough Corp. Q2 2008 Earnings Call Transcript
- Question-and-Answer Session[Operator Instructions]. Your first question comes from the line of Tim Anderson from Sanford Bernstein. Tim Anderson - Sanford Bernstein Hi. I have a couple of questions on your pipeline, which is just on your asenapine PDUFA, where are we, and what's your confidence level on giving a...
- Earnings calls 2008-07-21
- Schering-Plough Corp. Q4 2007 Earnings Call Transcript
- Question-and-Answer Session[Operator Instructions]. And your first question comes from Tim Anderson with Sanford Bernstein. Tim Anderson - Sanford Bernstein Couple of questions. On ENHANCE, can you just talk about, one data point that was in the January press release, which noted what the baseline IMT levels were which was...
- Earnings calls 2008-02-12
- << Previous
- page 1 of 1
- Next >>
